{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-004911","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2022-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.405772+00:00","generated_at":"2026-06-24T15:57:09.789605+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Odyssey Health completes Phase I SAD trial for concussion drug PRV-002; moving to MAD phase","bullets":["Phase I Single Ascending Dosing (SAD) completed with three cohorts; drug PRV-002 safe and well tolerated, no severe adverse events.","Cohort III (8 healthy volunteers) cleared; Safety Review Committee unanimously approved start of Multiple Ascending Dosing (MAD) Cohort I.","Intranasal delivery showed low blood levels of PRV-002, supporting targeted brain delivery hypothesis.","Company planning FDA meeting to present Phase I data; Phase II trial sites and study design under development.","Global concussion treatment market valued at $6.9B (2020), forecast to reach $8.9B by 2027 (Grandview Research)."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-004911","json":"https://secwatch.observer/filing/0001683168-22-004911.json","markdown":"https://secwatch.observer/filing/0001683168-22-004911.md","text":"https://secwatch.observer/filing/0001683168-22-004911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822004911/0001683168-22-004911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316822004911/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T15:57:09.789605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}